Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

While Trump’s executive order provides substantial power to Elon Musk’s DOGE effort, it’s not specifically targeted to health ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug ...

District Judge John Bates wrote the removals harm “everyday Americans, and most acutely, underprivileged Americans, seeking ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is ...

All but one Senate Republican voted for Kennedy, a controversial vaccine critic whose embrace of the “Make America Healthy ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...